Immune_JJ
hyperactivation_NN
of_IN
HIV-1-infected_JJ
T_NN
cells_NNS
mediated_VBD
by_IN
Tat_NN
and_CC
the_DT
CD28_NN
pathway_NN
._.

Human_JJ
immunodeficiency_NN
virus-type_NN
1_CD
-LRB-_-LRB-
HIV-1_NN
-RRB-_-RRB-
infection_NN
is_VBZ
characterized_VBN
by_IN
a_DT
chronic_JJ
state_NN
of_IN
immune_JJ
hyperactivation_NN
in_IN
patients_NNS
._.

Infection_NN
of_IN
human_JJ
peripheral_JJ
blood_NN
lymphocytes_NNS
with_IN
HIV-1_NN
in_FW
vitro_FW
resulted_VBD
in_IN
increased_VBN
interleukin-2_NN
-LRB-_-LRB-
IL-2_NN
-RRB-_-RRB-
secretion_NN
in_IN
response_NN
to_TO
T_NN
cell_NN
activation_NN
via_IN
the_DT
CD3_NN
and_CC
CD28_NN
receptors_NNS
._.

Expression_NN
of_IN
the_DT
HIV-1_NN
transactivator_NN
Tat_NN
recapitulated_VBD
this_DT
phenotype_NN
and_CC
was_VBD
associated_VBN
with_IN
increased_VBN
IL-2_NN
secretion_NN
in_IN
response_NN
to_TO
costimulation_NN
with_IN
CD3_NN
plus_CC
CD28_NN
._.

IL-2_NN
superinduction_NN
by_IN
Tat_NN
occurred_VBD
at_IN
the_DT
transcriptional_JJ
level_NN
,_,
was_VBD
mediated_VBN
by_IN
the_DT
CD28-responsive_JJ
element_NN
in_IN
the_DT
IL-2_NN
promoter_NN
,_,
and_CC
was_VBD
exclusively_RB
dependent_JJ
on_IN
the_DT
29_CD
amino_NN
acids_NNS
encoded_VBN
by_IN
the_DT
second_JJ
exon_NN
of_IN
Tat_NN
._.

